Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 635 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ketamine Clear all
Completed Phase 2 Interventional

Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19

NCT06821087
View directory record Official record
Conditions
Long COVID
Interventions
Ketamine only
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 4:20 PM EDT
Withdrawn Phase 3 Interventional

A Study to Decrease Suicidal Thinking Using Ketamine

NCT02418702
View directory record Official record
Conditions
Depression, Suicide
Interventions
0.2 mg/kg ketamine, placebo
Drug · Other
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2019 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Ketamine and Nitroprusside for Depression

NCT03102736
View directory record Official record
Conditions
Depression
Interventions
Placebos, Ketamine, Nitroprusside
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism

NCT02675530
View directory record Official record
Conditions
Schizophrenia
Interventions
ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Ketamine for Depression and Suicide Risk

NCT02094898
View directory record Official record
Conditions
Depression, Suicide
Interventions
Ketamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Jul 23, 2026, 4:20 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Ketamine and Propofol NeuroImaging

NCT07294092
View directory record Official record
Conditions
Anesthesia, Pain
Interventions
Propofol, Ketamine, Peripheral Nerve Stimulation
Drug · Device
Lead sponsor
Keith M Vogt
Other
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 23, 2026, 4:20 PM EDT
Withdrawn Phase 4 Interventional

Remifentanil Plus Ketamine for Dynamic Flexible Bronchoscopy

NCT03613792
View directory record Official record
Conditions
Bronchoscopy
Interventions
Remifentanil, Fentanyl, Midazolam, Ketamine
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 23, 2026, 4:20 PM EDT
Terminated Phase 2 Interventional Results available

A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder

NCT02234011
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation

NCT01191398
View directory record Official record
Conditions
Sialorrhea
Interventions
Atropine (0.01mg/kg), Glycopyrrolate (0.01mg/kg), Normal saline 0.9%
Drug
Lead sponsor
Craig J. Huang
Other
Eligibility
6 Months to 18 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 1 Interventional

Continuation Ketamine in Major Depression

NCT00548964
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lithium, Ketamine
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

NCT00985933
View directory record Official record
Conditions
Healthy, Memory Impairment
Interventions
AZD8529, Placebo to match AZD8529
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Jul 23, 2026, 4:20 PM EDT
Recruiting Phase 2 Interventional

Ketamine for Opioid Use Disorder

NCT06943859
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Treatment with Ketamine, Treatment with Very Low Dose Ketamine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)

NCT00749203
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, PTSD, Depression, Anxiety Disorder
Interventions
Midazolam, Ketamine
Drug
Lead sponsor
Dennis Charney
Other
Eligibility
21 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Jul 23, 2026, 4:20 PM EDT
Withdrawn Not applicable Interventional

The Effect of Ketamine in the Prevention of Hypoventilation in Patients Undergoing Deep Sedation Using Propofol and Fentanyl

NCT01825083
View directory record Official record
Conditions
Hypercarbia
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Jul 23, 2026, 4:20 PM EDT
Terminated Phase 2 Interventional Results available

Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

NCT01680172
View directory record Official record
Conditions
Cancer, Depression, Anxiety
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Scottsdale, Arizona • Yuma, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Jul 23, 2026, 4:20 PM EDT
Enrolling by invitation No phase listed Observational

Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements

NCT06002100
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
fNIRS measurement
Other
Lead sponsor
Kernel
Industry
Eligibility
18 Years to 75 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Costa Mesa, California • La Jolla, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Not applicable Interventional

Low Dose Ketamine as an Adjunct to Fentanyl in Outpatient Tonsillectomy

NCT00587665
View directory record Official record
Conditions
Pain
Interventions
ketamine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 12 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

NCT04032301
View directory record Official record
Conditions
Post-Traumatic Stress Disorders, Major Depressive Disorder
Interventions
Ketamine, Normal Saline
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain

NCT00899600
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Ketamine, Normal saline
Drug · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Jul 23, 2026, 4:20 PM EDT
Recruiting Phase 3 Interventional

Ketamine Treatment of Youth Suicide Attempters

NCT04763343
View directory record Official record
Conditions
Suicide, Attempted
Interventions
Ketamine Hydrochloride, Saline, CAMS Therapy
Drug · Behavioral
Lead sponsor
Tatiana Falcone, MD
Other
Eligibility
14 Years to 30 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 2 Interventional

Ketamine for the Treatment of Depression in Parkinson's Disease

NCT04944017
View directory record Official record
Conditions
Parkinson's Disease, Depression
Interventions
Ketamine Infusion, Placebo - Saline Infusion
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 23, 2026, 4:20 PM EDT
Completed Phase 4 Interventional Results available

ACL Repair and Multimodal Analgesia

NCT01868425
View directory record Official record
Conditions
Pain
Interventions
multimodal:acetaminophen, gabapentin, ketamine, bupivacaine, placebo pills and injectables
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 55 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Jul 23, 2026, 4:20 PM EDT
Recruiting Phase 2 Interventional

A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients

NCT05803551
View directory record Official record
Conditions
Depression
Interventions
Ketamine Hydrochloride, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jul 23, 2026, 4:20 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

NCT06383273
View directory record Official record
Conditions
Cataract
Interventions
MELT-300 sublingual tablet, Midalozam sublingual tablet, Placebo sublingual tablet
Drug
Lead sponsor
Melt Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Chico, California • Grand Junction, Colorado • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Jul 23, 2026, 4:20 PM EDT